JLM01

JLM01 is a therapeutic candidate developed by Jecho Biopharmaceuticals that is identified as being related to or a version of **liraglutide**, a glucagon-like peptide-1 (GLP-1) receptor agonist. The drug is uniquely positioned in the company's pipeline for two distinct therapeutic areas: **diabetes complications** and **mental health conditions**, specifically **paranoia**. As a GLP-1 analog, JLM01 mimics the action of the endogenous incretin hormone GLP-1, which regulates glucose metabolism by stimulating insulin secretion and inhibiting glucagon release. Beyond its metabolic effects, JLM01 is being investigated for psychiatric indications, likely leveraging the neuroprotective and neuromodulatory properties of GLP-1 receptors expressed in the central nervous system, which are thought to influence neuroinflammation and cognitive function.